cao亚洲欧美国产_成人毛片视频电影_男女爱视频免费高清在线观看_是一家值得信赖的金融服务机构_国产国产视频精品欧美视频_亚洲中文字幕久久私人影院_尤物在线精品视频_黄污网站在线观看_欧美日韩亚洲免费观看_国产剧情在线播放

On September 25, 2024,  Joint Biosciences announced that its first-in-class drug, OVV-01 (vesicular stomatitis virus-based injection of oncolytic therapy), has received dual IND clearances from the U.S. Food and Drug Administration (FDA) for both Phase II and Phase I clinical trials. This milestone is China’s first oncolytic virus product to have dual FDA IND clearances.

Dr. George Zhou, Founder and CEO of Joint Biosciences, stated: “We are thrilled to share this breakthrough. The safety and efficacy of OVV-01 have been preliminarily validated in phase I trial, and this clearance made a critical milestone in our R&D development, and reflects the FDA’s comprehensive recognition of OVV-01’s potential, elevating us from a preclinical status to a clinical-stage innovator.”

About OVV-01

OVV-01 is a recombinant vesicular stomatitis virus (VSV) engineered to carry the NY-ESO-1 tumor-associated antigen. It selectively replicates within tumor cells, releasing the highly immunogenic NY-ESO-1 antigen. This dual mechanism modulates the tumor immune microenvironment, induces tumor-specific immune responses, and promotes T-cell activation, expansion, and recruitment. By enhancing T-cell infiltration into tumors and counteracting immunosuppression, OVV-01 achieves potent antitumor activity.

About Joint Biosciences
Founded in 2020 and headquartered in Shanghai,  Joint Biosciences dedicates to First-in-Class and First-in-human therapeutic R&D. The company’s proprietary OVV and OVV-Drive-IO Platform integrates oncolytic viral vaccines with combination immunotherapy for solid and hematologic malignancies.